Immunotherapy with gene-modified T cells: limiting side effects provides new challenges

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Genetic engineering enables T-cell modification for enhanced anti-cancer activity.
• Chimeric antigen receptors (CAR) target cell surface molecules, while T-cell receptors (TCR) target intracellular proteins presented by HLA molecules.
• Clinical trials demonstrate significant patient responses using CAR T-cells (e.g., CD19 for leukemia) and TCR T-cells (e.g., MART-1, NY-ESO-1 for cancers).

Purpose of the Study:

• To review the factors contributing to toxic side effects in gene-modified T-cell therapy.
• To outline strategies for mitigating these toxicities while preserving anti-cancer efficacy.

Main Methods:

• Review of clinical trial data and scientific literature on CAR and TCR T-cell therapies.
• Analysis of on- and off-target toxicity mechanisms.
• Exploration of potential safety-enhancing strategies.

Main Results:

• CAR and TCR T-cell therapies have yielded dramatic clinical benefits in various cancers.
• Significant on- and off-target toxicities, including fatal complications, have been observed.
• Toxicity is a critical concern limiting the broader application of these therapies.

Conclusions:

• Gene-modified T-cell therapies offer potent anti-cancer potential but are associated with significant toxicities.
• Developing strategies to manage and reduce side effects is crucial for advancing T-cell therapy.
• Balancing anti-cancer activity with patient safety is paramount for successful therapeutic application.